Heavily Pre-Treated Patients With MM Respond to Cilta-Cel CAR-T Cell Therapy

Patients with multiple myeloma (MM) who had received multiple prior therapies, including B-cell maturation antigen (BCMA)–targeting agents, and had progressive disease responded to treatment with ciltacabtagene autoleucel (cilta-cel), resulting in measurable residual disease (MRD) negativity.